A novel, non-substrate-based series of glycine type 1 transporter inhibitors derived from high-throughput screening.

[1]  W. Shipe,et al.  Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. , 2006, Current topics in medicinal chemistry.

[2]  F. Iasevoli,et al.  Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. , 2005, Current pharmaceutical design.

[3]  Sviatlana Yahorava,et al.  New substituted piperazines as ligands for melanocortin receptors. Correlation to the X-ray structure of "THIQ". , 2004, Journal of medicinal chemistry.

[4]  D. Javitt,et al.  Glycine and d-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia , 2004, Brain Research.

[5]  A. Slassi,et al.  Recent progress in the use of glycine transporter-1 inhibitors for the treatment of central and peripheral nervous system diseases , 2004 .

[6]  D. Goff,et al.  Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia , 2003, Annals of the New York Academy of Sciences.

[7]  B. López-Corcuera,et al.  Structure, function and regulation of glycine neurotransporters. , 2003, European journal of pharmacology.

[8]  J. Lowe,et al.  [3H]-(R)-NPTS, a radioligand for the type 1 glycine transporter. , 2003, Bioorganic & medicinal chemistry letters.

[9]  D. Javitt,et al.  The role of N-Methyl-D-Aspartate (NMDA) receptor-mediated neurotransmission in the pathophysiology and therapeutics of psychiatric syndromes , 1998, European Neuropsychopharmacology.

[10]  F. Berardi,et al.  Synthesis and dopamine receptor affinities of 1-aminoethylhetero-tetralines , 1991 .

[11]  R. Narendran,et al.  Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. , 2005, Clinical therapeutics.

[12]  C. Sur,et al.  Glycine Site Modulators and Glycine Transporter-1 Inhibitors as Novel Therapeutic Targets for the Treatment of Schizophrenia , 2005 .

[13]  D. Javitt,et al.  Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. , 1999, Archives of general psychiatry.